Posters
Always at the forefront of the dynamic patient-derived xenograft (PDX) market, Champions Oncology has emerged as a respected key opinion leader on the utilization and benefits of PDX models in oncology drug development.
2022
2021
SITC 2021: 3D Co-Culture Platform Reveals Insights into Patient Autologous Immune Cell-Tumor Interaction and Immune Modulation In Vitro
2020
2019
SITC 2019: Development of a Natural Killer (NK) ImmunoGraft® Platform for the Evaluation of Pharmacodynamics of Immuno Oncology Therapeutics
2018
EORTC 2018: Establishment of ImmunoGraft® with Human Immune System (HIS) and PDX Co-Engraftment Using NOG-EXL Mice to Evaluate Checkpoint Inhibitors
SITC 2018: Autologous Human Immune System (HIS) ImmunoGraft®: Mobilized Peripheral Blood (MPB) Derived CD34 Engraftment and Lineage Development